Oncology
Conference Coverage
Pemetrexed Continuation Maintenance Slows NSCLC Progression
Major Finding: Pemetrexed maintenance therapy plus best supportive care after pemetrexed/cisplatin induction reduced the risk of progression by 38...
News
Longer Imatinib Therapy Improves Outcomes For High-Risk GIST
Major Finding: Compared with their counterparts who were given imatinib for just 1 year after surgery, patients who were given imatinib for 3...
News
Ipilimumab Added to Dacarbazine Prolongs Survival for Metastatic Melanoma
Major Finding: Nearly 21% of 250 metastatic melanoma patients who underwent first-line treatment with ipilimumab (Yervoy, Bristol-Myers Squibb) in...
News
BRAF Inhibitor Cuts Death Risk in Advanced Melanoma
Major Finding: Survival estimates at a median 3 months’ of follow-up suggest 84% of patients treated with vemurafenib would be alive at 6 months...
News
Survey Highlights Survivor Care Issues
Major Finding: Primary care physicians were significantly more likely than oncologists to express concern about adequate training to manage...
News
Bevacizumab Shows Promise for High-Risk Ovarian Cancer
Major Finding: Relative to chemotherapy alone, chemotherapy plus bevacizumab was associated with a nonsignificant 15% reduction in the risk of...
News
Bevacizumab Halves Progression Risk in Recurrent Ovarian Cancer
Major Finding: Compared with patients assigned to chemotherapy plus placebo, patients assigned to chemotherapy plus bevacizumab had a 52%...
News
Crizotinib Continues to Produce High Response in ALK+ NSCLC
Major Finding: In an ongoing phase I trial, the overall response rate to crizotinib was 61%, and the median duration of response was 48 weeks.Data...
News
Exemestane Prevents 65% of Invasive Breast Cancers in Postmenopausal Women
Major Finding: The annual incidence of invasive breast cancer was 0.19% with exemestane vs. 0.55% with placebo (hazard ratio 0.35, P = .002).Data...
News
HPV-Related Oral Cancer Incidence Spikes Sharply
Major Finding: Between 1988 and 2004, the incidence of HPV-positive oropharyngeal cancers increased 225%.
News
Adjuvant Chemotherapy Delay Worsens Survival After Colorectal Surgery
Major Finding: Each 4 weeks of delay beyond 1 month after curative resection of colorectal cancer is associated with a 14% decrease in overall and...